## FWO DMP Template - Flemish Standard Data Management Plan

## **Version KU Leuven**

Project supervisors (from application round 2018 onwards) and fellows (from application round 2020 onwards) will, upon being awarded their project or fellowship, be invited to develop their answers to the data management related questions into a DMP. The FWO expects a **completed DMP no later than 6 months after the official start date** of the project or fellowship. The DMP should not be submitted to FWO but to the research co-ordination office of the host institute; FWO may request the DMP in a random check.

At the end of the project, the **final version of the DMP** has to be added to the final report of the project; this should be submitted to FWO by the supervisor-spokesperson through FWO's e-portal. This DMP may of course have been updated since its first version. The DMP is an element in the final evaluation of the project by the relevant expert panel. Both the DMP submitted within the first 6 months after the start date and the final DMP may use this template.

The DMP template used by the Research Foundation Flanders (FWO) corresponds with the Flemish Standard Data Management Plan. This Flemish Standard DMP was developed by the Flemish Research Data Network (FRDN) Task Force DMP which comprises representatives of all Flemish funders and research institutions. This is a standardized DMP template based on the previous FWO template that contains the core requirements for data management planning. To increase understanding and facilitate completion of the DMP, a standardized **glossary** of definitions and abbreviations is available via the following link.

	1. General Project Information
Name Grant Holder & ORCID	Wouter Peelaerts https://orcid.org/0000-0003-3776-4162
Contributor name(s) (+ ORCID) & roles	Wouler 1 ceraer is https://orcid.org/0000-0003-3770-4102
Project number <sup>1</sup> & title	GOAOB24N Urinary tract infections as a trigger of oligodendrogliopathy in multiple system atrophy
Funder(s) GrantID <sup>2</sup>	D-2024-2895
Affiliation(s)	✓ KU Leuven
	☐ Universiteit Antwerpen
	□ Universiteit Gent
	☐ Universiteit Hasselt
	□ Vrije Universiteit Brussel
	□ Other:
	ROR identifier KU Leuven: 05f950310
Please provide a short project description	Neurodegenerative diseases are often accompanied by microbial infections, even long before a clinical diagnosis is made. Given that infections occur more frequently in people with brain disorders, this has led to the hypothesis that neurodegeneration can be precipitated by infection. Multiple system atrophy (MSA) is a white matter disease of the brain for which infections, such as urinary tract infections (UTIs) are unusually frequent. Even though UTIs are prominent in MSA, it is not known if UTIs can impact MSA. Research from our team has shown that UTIs can trigger and transmit pathology from the urogenital system to the central nervous system, reminiscent of MSA.
	The overarching hypothesis of this work is that MSA can be triggered by urogenital infections. This project will study how infections can impact brain function by defining the pathogen-host mechanisms that elicit a central response. The study of brain white matter cells, oligodendrocytes, is highly challenging, as few tools are available to study these cells. By using novel oligodendrocyte-based disease models, this work will allow to dissect the mechanisms associated with peripheral infection and their effect on the brain. The goals are to map the immunological and pathological fingerprint of MSA and unravel proximal disease mechanisms. This could lead to a conceptual leap forward in our understanding of how MSA originates and how the periphery interacts with the brain during

<sup>&</sup>lt;sup>1</sup> "Project number" refers to the institutional project number. This question is optional. Applicants can only provide one project number.

<sup>2</sup> Funder(s) GrantID refers to the number of the DMP at the funder(s), here one can specify multiple GrantIDs if multiple funding sources were used.

## 2. Research Data Summary

List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data <sup>3</sup>.

				ONLY FOR DIGITAL DATA	ONLY FOR DIGITAL DATA	ONLY FOR DIGITAL DATA	ONLY FOR PHYSICAL DATA
Dataset Name	Description	New or Reused	Digital or Physical	Digital Data Type	Digital Data Format	Digital Data Volume (MB, GB, TB)	Physical Volume
Experimental	Behavioural redout	<ul><li>☑ Generate new data</li><li>☐ Reuse existing data</li></ul>	⊠ Digital □ Physical		• MOV (.mov) • TXT (.txt) • XLS (.xls)		
Experimental	Single cell RNA data	⊠ Generate new data □ Reuse existing data	⊠ Digital □ Physical	☐ Audiovisual ☐ Images ☐ Sound ☐ Numerical ☒ Textual ☐ Model ☐ Software ☐ Other:	☐ FASTQ (.fastq or .fq): Contains raw sequencing reads and quality scores. ☐ BAM/SAM (.bam or .sam): Binary/Sequence Alignment Map files containing aligned sequences.	□ < 1 GB □ < 100 GB □ < 1 TB □ < 5 TB ⊠ > 5 TB □ NA	

<sup>&</sup>lt;sup>3</sup> Add rows for each dataset you want to describe.

Experimental	Tissue for histology and	<ul> <li>☑ Generate new data</li> <li>☐ Reuse existing</li> </ul>	☑ Digital ☐ Physical	☐ Audiovisual 図 Images	☐ HDF5 (.h5): Hierarchical Data Format, often used for storing processed data. ☐ CSV/TSV (.csv or .tsv): Comma/Tab- separated values files for expression matrices. ☐ MTX (.mtx): Matrix Market format for sparse matrices.  • TXT (.txt) • XLS (.xls)	□ < 1 GB □ < 100 GB	
	microscopy	data	j	□ Sound     ⋈ Numerical     □ Textual     □ Model     □ Software     □ Other:	• SVS (.svs) TIFF (Tagged Image File Format	□ < 1 TB □ < 5 TB □ > 5 TB □ NA	
Experimental	Tissue for histology and confocal microscopy	<ul><li>☑ Generate new data</li><li>☐ Reuse existing data</li></ul>	⊠ Digital □ Physical	□ Audiovisual     □ Images     □ Sound     □ Numerical     □ Textual     □ Model     □ Software     □ Other:	<ul><li>IMG (.img)</li><li>CVS (.cvs)</li></ul>	□ < 1 GB □ < 100 GB ⊠ < 1 TB □ < 5 TB □ > 5 TB □ NA	

Experimental	Cytokine	☐ Generate new data	□ Digital	☐ Audiovisual	XLS (.xls)	$\boxtimes$ < 1 GB
	analysis from	$\square$ Reuse existing	☐ Physical	☐ Images	, ,	□ < 100 GB
	animal plasma	data		☐ Sound		$\square$ < 1 TB
	or urine					$\square$ < 5 TB
				☐ Textual		$\square > 5 \text{ TB}$
				□ Model		□NA
				☐ Software		
				☐ Other:		
Experimental	Flow cytometry	☐ Generate new data	□ Digital	☐ Audiovisual	XLS (.xls)	□ < 1 GB
_		☐ Reuse existing	☐ Physical	☐ Images	• FCS (.fcs)	⊠ < 100 GB
		data	_			$\square$ < 1 TB
						$\square$ < 5 TB
				☐ Textual		$\square > 5 \text{ TB}$
				☐ Model		□NA
				☐ Software		
				☐ Other:		
Experimental	Infectious titers	⊠ Generate new data	□ Digital	☐ Audiovisual	XLS (.xls)	⊠ < 1 GB
		⊠ Reuse existing	□ Physical	$\square$ Images		□ < 100 GB
		data				$\square < 1 \text{ TB}$
						$\square$ < 5 TB
				☐ Textual		$\square > 5 \text{ TB}$
				☐ Model		$\square$ NA
				☐ Software		
				☐ Other:		
Experimental	Plasmid maps	☐ Generate new data	$\boxtimes$ Digital	☐ Audiovisual	☐ GenBank (.gb	$\boxtimes$ < 1 GB
		$\square$ Reuse existing	☐ Physical	$\square$ Images	or .gbk)	$\square < 100 \text{ GB}$
		data				$\square < 1 \text{ TB}$
				☐ Numerical	$\Box$ FASTA	$\square < 5 \text{ TB}$
				☐ Textual	(.fasta or .fa): A	$\square > 5 \text{ TB}$
				□ Model	text-based format	□ NA
				☐ Software	for representing	
				☐ Other:	nucleotide	

	sequences. It includes the sequence data but lacks detailed annotations present in GenBank files.	
	□VectorBuilder' s Proprietary Format (.vbp): This format may be used for specific features unique to VectorBuilder's platform, ensuring compatibility with their online tools and services.	

If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type.  Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.  Will you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type where appropriate.	ranging from raw data to processed and analysed data valuable, difficult to replace and/or ethical issues are a	IP, so make sure it is detailed and complete. It includes digital and physical data and encompasses the whole spectrum a including analysis scripts and code. Physical data are all materials that need proper management because they are associated. Materials that are not considered data in an RDM context include your own manuscripts, theses and aur datasets and should described under documentation/metadata.
(e.g. DOI, Handle, URL etc.) per dataset or data type.  Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.  Will you process personal data <sup>o</sup> ? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type    Yes, human subject data; provide SMEC or EC approval number:   Yes, dual use; provide approval number: 052 /2023   Yes, dual use; provide approval number: 050 /2023   Yes, dual use; provide PRET G-number or EC S-number below)   Xes (provide PRET G-nu		
Are there any ethical issues concerning the creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.  Will you process personal data? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type		
creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.  Will you process personal data <sup>o</sup> ? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  Yes, animal data; provide ECD reference number: 052 /2023  Yes, animal data; provide ECD reference number: 052 /2023  Yes, dual use; provide approval number:  No Additional information:  Yes (provide PRET G-number or EC S-number below)  No Additional information:  No No Migres when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type	type.	
creation and/or use of the data (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.  Will you process personal data <sup>o</sup> ? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  Yes, animal data; provide ECD reference number: 052 /2023  Yes, animal data; provide ECD reference number: 052 /2023  Yes, dual use; provide approval number:  No Additional information:  Yes (provide PRET G-number or EC S-number below)  No Additional information:  No No Migres when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type	A d d: 1:	
(e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number.  Will you process personal data⁴? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  □ Yes, dual use; provide approval number: □ No Additional information: □ Yes (provide PRET G-number or EC S-number below) □ No Additional information: □ Yes □ No If yes, please comment:		
when appropriate and provide the relevant ethical approval number.  Additional information:  Will you process personal data <sup>4</sup> ? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  Additional information:  □ Yes (provide PRET G-number or EC S-number below)  □ No  Additional information:  □ Yes  □ No  If yes, please comment:		
will you process personal data <sup>1</sup> ? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  □ Yes (provide PRET G-number or EC S-number below) □ No Additional information: □ Yes □ No If yes, please comment:	use)? If so, refer to specific datasets or data types	
to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type    No	** *	Additional information:
to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type    No	Will you process personal data <sup>4</sup> ? If so, please refer	☐ Yes (provide PRET G-number or EC S-number below)
privacy register number (G or S number).  Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  □ Yes □ No □ If yes, please comment: □ Yes □ No □ If yes, please comment:	· · ·	,
Does your work have potential for commercial valorization (e.g. tech transfer, for example spinoffs, commercial exploitation,)?  If so, please comment per dataset or data type  □ Yes □ No If yes, please comment:	·	Additional information:
valorization (e.g. tech transfer, for example spin- offs, commercial exploitation,)?  If so, please comment per dataset or data type     No  If yes, please comment:	privacy register number (G or S number).	
offs, commercial exploitation,)?  If yes, please comment:  If yes, please comment:		
If so, please comment per dataset or data type		
71		If yes, please comment:
	, 1	

<sup>&</sup>lt;sup>4</sup> See Glossary Flemish Standard Data Management Plan

Do existing 3rd party agreements restrict	⊠ Yes
exploitation or dissemination of the data you	□ No
(re)use (e.g. Material/Data transfer agreements,	If yes, please explain: use of induced pluripotent stem cells (iPSCs). Cells were obtained from the European
research collaboration agreements)?	biobank EBISC under MTA. There are restrictions in place in case of any commercial use (which does not
If so, please explain to what data they relate and	apply).
what restrictions are in place.	
Are there any other legal issues, such as	□ Yes
intellectual property rights and ownership, to be	$\boxtimes$ No
managed related to the data you (re)use?	If yes, please explain:
If so, please explain to what data they relate and	
which restrictions will be asserted.	

## 3. Documentation and Metadata

Clearly describe what approach will be followed to capture the accompanying information necessary to keep **data understandable and usable**, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information is recorded).

RDM guidance on documentation and metadata.

All data will be kept in electronic labbooks (OneNote). These labbooks can be shared between labmembers and will be updated daily. Links to new data can be copied within the electronic labbook to the original file data so that new data can be retrieved easily.

Small data will be stored on the KU Leuven J drive.

Large data will be stored on the KU Leuven L drive.

Very large data (scanned tissue slides) will be stored on a separate KU Leuven exchange drive.

Will a metadata standard be used to make it	⊠ Yes
easier to find and reuse the data?	$\square$ No
	If yes, please specify (where appropriate per dataset or data type) which metadata standard will be used:
If so, please specify which metadata standard	
will be used. If not, please specify which	Date_experimental method_experimental ID_person initials.file extension
metadata will be created to make the data easier	
to find and reuse.	If no, please specify (where appropriate per dataset or data type) which metadata will be created:
REPOSITORIES COULD ASK TO DELIVER METADATA IN A CERTAIN FORMAT, WITH SPECIFIED ONTOLOGIES AND VOCABULARIES, I.E. STANDARD LISTS WITH UNIQUE IDENTIFIERS.	

4. Data Storage & Back-up during the Research Project		
Where will the data be stored?	⊠ Shared network drive (J-drive)	
	☐ Personal network drive (I-drive)	
Consult the interactive KU Leuven storage guide to	☐ OneDrive (KU Leuven)	
find the most suitable storage solution for your data.	☐ Sharepoint online	
	☐ Sharepoint on-premis	
	☐ Large Volume Storage	
	☐ Digital Vault	
	☐ Other:	
How will the data be backed up?	⊠ Standard back-up provided by KU Leuven ICTS for my storage solution	
	☐ Personal back-ups I make (specify)	
WHAT STORAGE AND BACKUP PROCEDURES WILL BE IN	$\square$ Other (specify)	
PLACE TO PREVENT DATA LOSS?		

Is there currently sufficient storage & backup	⊠ Yes
capacity during the project? If yes, specify	□ No
concisely. If no or insufficient storage or backup	
capacities are available, then explain how this	If no, please specify:
will be taken care of.	
How will you ensure that the data are securely	We will use KU Leuven data storage drives
stored and not accessed or modified by	
unauthorized persons?	
CLEARLY DESCRIBE THE MEASURES (IN TERMS OF PHYSICAL	
SECURITY, NETWORK SECURITY, AND SECURITY OF COMPUTER	
SYSTEMS AND FILES) THAT WILL BE TAKEN TO ENSURE THAT STORED AND TRANSFERRED DATA ARE SAFE.	
Guidance on security for research data	
What are the expected costs for data storage and	Costs will be covered by project funding.
backup during the research project? How will	
these costs be covered?	Estimated costs is between 200 and 400 euros per year.
	5. Data Preservation after the end of the Research Project
Which data will be retained for at least five years	
	⊠ All data will be preserved for 10 years according to KU Leuven RDM policy
(or longer, in agreement with other retention	☐ All data will be preserved for 25 years according to CTC recommendations for clinical trials with
_	☐ All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans
(or longer, in agreement with other retention	☐ All data will be preserved for 25 years according to CTC recommendations for clinical trials with
(or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved,	☐ All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans
(or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this	☐ All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans
(or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved,	☐ All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans

Guidance on data preservation

Where will these data be archived (stored and curated for the long-term)?  Dedicated data repositories are often the best place to preserve your data. Data not suitable for preservation in a repository can be stored using a KU Leuven storage solution, consult the interactive KU Leuven storage guide.	<ul> <li>□ KU Leuven RDR</li> <li>⋈ Large Volume Storage (longterm for large volumes)</li> <li>□ Shared network drive (J-drive)</li> <li>□ Other (specifiy):</li> </ul>
What are the expected costs for data preservation during the expected retention period? How will these costs be covered?	Costs will be covered by project funding.  Estimated costs is between 200 and 400 euros per year.
	6. Data Sharing and Reuse
Will the data (or part of the data) be made available for reuse after/during the project? Please explain per dataset or data type which data will be made available.  Note that 'Available' does not necessarily mean that the data set becomes openly available, conditions for access and use may apply. Availablity in this question thus entails both open & restricted access. For more information:  https://wiki.surfnet.nl/display/standards/info-eu-repo/#infoeurepo-AccessRights	<ul> <li>☐ Yes, as open data</li> <li>☐ Yes, as embargoed data (temporary restriction)</li> <li>☑ Yes, as restricted data (upon approval, or institutional access only)</li> <li>☐ No (closed access)</li> <li>☐ Other, please specify:</li> </ul>

Team members

If access is restricted, please specify who will be

able to access the data and under what

conditions.

Are there any factors that restrict or prevent the	☐ Yes, privacy aspects
sharing of (some of) the data (e.g. as defined in	☐ Yes, intellectual property rights
an agreement with a 3rd party, legal	☐ Yes, ethical aspects
restrictions)? Please explain per dataset or data	☐ Yes, aspects of dual use
type where appropriate.	☐ Yes, other
	⊠ No
	If yes, please specify:
	if yes, please specify.
Where will the data be made available?	⊠ KU Leuven RDR
If already known, please provide a repository per	☐ Other data repository (specify)
dataset or data type.	$\square$ Other (specify)
When will the data be made available?	☐ Upon publication of research results
	☐ Specific date (specify)
	$\square$ Other (specify)
Which data usage licenses are you going to	☐ CC-BY 4.0 (data)
provide? If none, please explain why.	□ Data Transfer Agreement (restricted data)
	☐ MIT licence (code)
A DATA USAGE LICENSE INDICATES WHETHER THE DATA CAN	☐ GNU GPL-3.0 (code)
BE REUSED OR NOT AND UNDER WHAT CONDITIONS. IF NO	$\square$ Other (specify)
LICENCE IS GRANTED, THE DATA ARE IN A GREY ZONE AND	
CANNOT BE LEGALLY REUSED. DO NOTE THAT YOU MAY ONLY RELEASE DATA UNDER A LICENCE CHOSEN BY YOURSELF IF IT	
DOES NOT ALREADY FALL UNDER ANOTHER LICENCE THAT	
MIGHT PROHIBIT THAT.	
Check the RDR guidance on licences for data and	
software sources code or consult the <u>License selector</u>	
tool to help you choose.	

Do you intend to add a PID/DOI/accession number to your dataset(s)? If already available, please provide it here.	<ul> <li>☐ Yes, a PID will be added upon deposit in a data repository</li> <li>☐ My dataset already has a PID</li> <li>☒ No</li> </ul>
INDICATE WHETHER YOU INTEND TO ADD A PERSISTENT AND UNIQUE IDENTIFIER IN ORDER TO IDENTIFY AND RETRIEVE THE DATA.	
What are the expected costs for data sharing? How will these costs be covered?	We expect no costs for data sharing

7. Responsibilities	
Who will manage data documentation and metadata during the research project?	Wouter Peelaerts (PI) and Joris Van Asselberghs (senior technician) will manage all data on a common storage drive that is automatically backed up.
Who will manage data storage and backup during the research project?	Joris Van Asselberghs (senior technician)
Who will manage data preservation and sharing?	Joris Van Asselberghs (senior technician)
Who will update and implement this DMP?	Wouter Peelaerts (PI)